Feasibility and Preliminary Effectiveness of Varenicline for Treating Co-Occurring Cannabis and Tobacco Use

References

• Agrawal, A., and M. Lynskey. 2009. Tobacco and cannabis co-occurrence: Does route of administration matter? Drug and Alcohol Dependence 99:240–47. doi:10.1016/j.drugalcdep.2008.08.007.
   PubMed Web of Science ®Google Scholar
• Agrawal, A., P. Madden, K. Bucholz, A. Heath, and M. Lynskey. 2008. Transitions to regular smoking and to nicotine dependence in women using cannabis. Drug and Alcohol Dependence 95:107–14. doi:10.1016/j.drugalcdep.2007.12.017.
   PubMed Web of Science ®Google Scholar
• Anthenelli, R. M., N. L. Benowitz, R. West, L. St Aubin, T. McRae, D. Lawrence, J. Ascher, C. Russ, A. Krishen, and A. E. Evins. 2016. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): A double-blind, randomised, placebo-controlled clinical trial. Lancet 387 (10037):2507–20. doi:10.1016/S0140-6736(16)30272-0.
   PubMed Web of Science ®Google Scholar
• Becker, J., S. Haug, T. Kraemer, and M. P. Schaub. 2015. Feasibility of a group cessation program for co-smokers of cannabis and tobacco. Drug and Alcohol Review 34 (4):418–26. doi:10.1111/dar.12244.
   PubMed Web of Science ®Google Scholar
• Belanger, R., C. Akre, E. Kuntsche, G. Gmel, and J.-C. Suris. 2011. Adding tobacco to cannabis: Its frequency and likely implications. Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco 13:746–50. doi:10.1093/ntr/ntr043.
   PubMed Web of Science ®Google Scholar
• Budney, A., R. Roffman, R. Stephens, and D. Walker. 2007. Marijuana dependence and its treatment. Addiction Science & Clinical Practice 4:4–16. doi:10.1151/ASCP07414.
   PubMedGoogle Scholar
• Budney, A. J., P. L. Novy, and J. R. Hughes. 1999. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 94 (9):1311–22. doi:10.1046/j.1360-0443.1999.94913114.x.
   PubMed Web of Science ®Google Scholar
• Center for Behavioral Health Statistics and Quality. 2015. Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15-4927, NSDUH Series H-50). http://www.samhsa.gov/data/
   Google Scholar
• De Dios, M. A., B. J. Anderson, C. M. Caviness, and M. D. Stein. 2014. Early quit days among methadone-maintained smokers in a smoking cessation trial. Nicotine & Tobacco Research 16 (11):1463–69. doi:10.1093/ntr/ntu099.
   PubMed Web of Science ®Google Scholar
• De Dios, M. A., E. L. Vaughan, C. A. Stanton, and R. Niaura. 2009. Adolescent tobacco use and substance abuse treatment outcomes. Journal of Substance Abuse Treatment 37 (1):17–24. doi:10.1016/j.jsat.2008.09.006.
   PubMed Web of Science ®Google Scholar
• Gonzales, D., S. I. Rennard, M. Nides, C. Oncken, S. Azoulay, C. B. Billing, E. J. Watsky, J. Gong, K. E. Williams, and K. R. Reeves, for the Varenicline Phase 3 Study Group. (2006). Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 296 (1):47–55. doi: 10.1001/jama.296.1.47.
   PubMed Web of Science ®Google Scholar
• Haney, M., G. Bedi, Z. D. Cooper, A. Glass, S. K. Vosburg, S. D. Comer, and R. W. Foltin. 2013. Predictors of marijuana relapse in the human laboratory: Robust impact of tobacco cigarette smoking status. Biological Psychiatry 73 (3):242–48. doi:10.1016/j.biopsych.2012.07.028.
   PubMed Web of Science ®Google Scholar
• Heishman, S. J., E. G. Singleton, and A. Liguori. 2001. Marijuana craving questionnaire: Development and initial validation of a self-report instrument. Addiction 96 (7):1023–34. doi:10.1046/j.1360-0443.2001.967102312.x.
   PubMed Web of Science ®Google Scholar
• Hill, K. P., L. H. Toto, S. E. Lukas, R. D. Weiss, G. H. Trksak, J. M. Rodolico, and S. F. Greenfield. 2013. Cognitive behavioral therapy and the nicotine transdermal patch for dual nicotine and cannabis dependence: A pilot study. The American Journal on Addictions 22 (3):233–38. doi:10.1111/j.1521-0391.2012.12007.x.
   PubMed Web of Science ®Google Scholar
• Jorenby, D., J. T. Hays, N. A. Rigotti, S. Azoulay, E. J. Watsky, K. E. Williams, C. B. Billing, J. Gong, and K. R. Reeves, for the Varenicline Phase 3 Study Group. (2006). Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA 296 (1):56–63. doi: 10.1001/jama.296.1.56.
   PubMed Web of Science ®Google Scholar
• Lee, D. C., A. J. Budney, M. F. Brunette, J. R. Hughes, J. F. Etter, and C. Stanger. 2014. Treatment models for targeting tobacco use during treatment for cannabis use disorder: Case series. Addictive Behaviors 39 (8):1224–30. doi:10.1016/j.addbeh.2014.04.010.
   PubMed Web of Science ®Google Scholar
• Marshall, K., L. Gowing, R. Ali, and B. Le Foll. 2014. Pharmacotherapies for cannabis dependence. Cochrane Database of Systematic Reviews (Online) 12:CD008940.
   PubMed Web of Science ®Google Scholar
• Mihalak, K. B., F. I. Carroll, and C. W. Luetje. 2006. Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors. Molecular Pharmacology 70 (3):801–05. doi:10.1124/mol.106.025130.
   PubMed Web of Science ®Google Scholar
• Mitchell, J. M., C. H. Teague, A. S. Kayser, S. E. Bartlett, and H. L. Fields. 2012. Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology 223 (3):299–306. doi:10.1007/s00213-012-2717-x.
   PubMed Web of Science ®Google Scholar
• Moitra, E., B. J. Anderson, and M. D. Stein. 2013. Perceived stress and substance use in methadone-maintained smokers. Drug and Alcohol Dependence 133 (2):785–88. doi:10.1016/j.drugalcdep.2013.08.010.
   PubMed Web of Science ®Google Scholar
• Moore, B., and A. Budney. 2001. Tobacco smoking in marijuana-dependent outpatients. Journal of Substance Abuse 13:583–96. doi:10.1016/S0899-3289(01)00093-1.
   PubMedGoogle Scholar
• Nahvi, S., Y. Ning, K. S. Segal, K. P. Richter, and J. H. Arnsten. 2014. Varenicline efficacy and safety among methadone maintained smokers: A randomized placebo-controlled trial. Addiction 109 (9):1554–63. doi:10.1111/add.2014.109.issue-9.
   PubMed Web of Science ®Google Scholar
• Newcombe, D. A., N. Walker, J. Sheridan, and S. Galea. 2015. The effect of varenicline administration on cannabis and tobacco use in cannabis and nicotine dependent individuals: A case series. Journal of Addiction Research & Therapy 6 (2):1–5. doi:10.4172/2155-6105.1000222.
   PubMedGoogle Scholar
• Patton, G., C. Coffey, J. Carlin, S. Sawyer, and M. Lynskey. 2005. Reverse gateways? Frequent cannabis use as a predictor of tobacco initiation and nicotine dependence. Addiction 100:1518–25. doi:10.1111/add.2005.100.issue-10.
   PubMed Web of Science ®Google Scholar
• Penetar, D. M., E. M. Kouri, M. M. Gross, E. M. McCarthy, C. K. Rhee, E. N. Peters, and S. E. Lukas. 2005. Transdermal nicotine alters some of marihuana’s effects in male and female volunteers. Drug and Alcohol Dependence 79 (2):211–23. doi:10.1016/j.drugalcdep.2005.01.008.
   PubMed Web of Science ®Google Scholar
• Plebani, J. G. 2012. Results of an initial clinical trial of varenicline for the treatment of cocaine dependence. Drug and Alcohol Dependence 121 (1–2):163–66. doi:10.1016/j.drugalcdep.2011.08.025.
   Web of Science ®Google Scholar
• Plebani, J. G., K. G. Lynch, L. Rennert, H. M. Pettinati, C. P. O’Brien, and K. M. Kampman. 2013. Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence. Drug and Alcohol Dependence 133 (2):754–58. doi:10.1016/j.drugalcdep.2013.06.019.
   PubMed Web of Science ®Google Scholar
• Posner, K., M. A. Oquendo, M. Gould, B. Stanley, and M. Davies. 2007. Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of suicidal events in the FDA’s pediatric suicidal risk analysis of antidepressants. The American Journal of Psychiatry 164 (7):1035–43. doi:10.1176/ajp.2007.164.7.1035.
   PubMed Web of Science ®Google Scholar
• Rabin, R. A., and T. P. George. 2015. A review of co-morbid tobacco and cannabis use disorders: Possible mechanisms to explain high rates of co-use. The American Journal on Addictions/American Academy of Psychiatrists in Alcoholism and Addictions 24 (2):105–16. doi:10.1111/ajad.v24.2.
   PubMed Web of Science ®Google Scholar
• Ramo, D., and J. Prochaska. 2012. Prevalence and co-use of marijuana among young adult cigarette smokers: An anonymous online national survey. Addiction Science & Clinical Practice 7 (1):5. doi:10.1186/1940-0640-7-5.
   PubMedGoogle Scholar
• Richter, K. P., C. A. Gibson, J. S. Ahluwalia, and K. H. Schmelzle. 2001. Tobacco use and quit attempts among methadone maintenance clients. American Journal of Public Health 91 (2):296–99. doi:10.2105/AJPH.91.2.296.
   PubMed Web of Science ®Google Scholar
• Rohsenow, D. J., J. W. Tidey, R. A. Martin, S. M. Colby, R. M. Swift, L. Leggio, and P. M. Monti. 2017. Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: Effects on smoking, substance use and depressive symptoms. Addiction 112 (10):1808–1820. doi: 10.1111/add.13861.
   Google Scholar
• Schauer, G. L., C. J. Berg, M. C. Kegler, D. M. Donovan, and M. Windle. 2016. Differences in tobacco product use among past month adult marijuana users and nonusers: Findings from the 2003–2012 national survey on drug use and health. Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco 18 (3):281–88. doi:10.1093/ntr/ntv093.
   PubMed Web of Science ®Google Scholar
• Sheehan, D. V., Y. Lecrubier, K. H. Sheehan, P. Amorim, J. Janavs, E. Weiller, T. Hergueta, R. Baker, and G. C. Dunbar. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 59 (Suppl 20):22–33;quiz 34–57.
   PubMedGoogle Scholar
• Solinas, M., M. Scherma, L. Fattore, J. Stroik, C. Wertheim, G. Tanda, W. Fratta, and S. R. Goldberg. 2007. Nicotinic alpha 7 receptors as a new target for treatment of cannabis abuse. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 27 (21):5615–20. doi:10.1523/JNEUROSCI.0027-07.2007.
   PubMed Web of Science ®Google Scholar
• Stein, M. D., C. M. Caviness, M. E. Kurth, D. Audet, J. Olson, and B. J. Anderson. 2013. Varenicline for smoking cessation among methadone-maintained smokers: A randomized clinical trial. Drug and Alcohol Dependence 133 (2):486–93. doi:10.1016/j.drugalcdep.2013.07.005.
   PubMed Web of Science ®Google Scholar
• Timberlake, D. S., B. C. Haberstick, C. J. Hopfer, J. Bricker, J. T. Sakai, J. M. Lessem, and J. K. Hewitt. 2007. Progression from marijuana use to daily smoking and nicotine dependence in a national sample of U.S. adolescents Drug and Alcohol Dependence 88 (2–3):272–81. doi:10.1016/j.drugalcdep.2006.11.005.
   Web of Science ®Google Scholar
• Volkow, N. D., R. D. Baler, W. M. Compton, and S. R. Weiss. 2014. Adverse health effects of marijuana use. The New England Journal of Medicine 370 (23):2219–27. doi:10.1056/NEJMra1402309.
   PubMed Web of Science ®Google Scholar